![]() To view the most recent and complete version of the guideline, go online to Ħ Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.5.2021.© National Comprehensive Cancer Network, Inc. J ThoracOncol 2017 12(2):258-68.ĥ Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Esophageal and Esophagogastric Junction Cancers V.3.2021.© National Comprehensive Cancer Network, Inc. Clinical impact of hybrid capture-based next-generation sequencing on changes in treatment decisions in lung cancer. Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in “driver-negative”lung adenocarcinomas. Supporting Precision Oncology: Targeted Therapies, Immuno-oncology, and Predictive Biomarker-Based Medicines. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019. Clinical and analytic validation of FoundationOne CDx for NTRK fusion-positive solid tumors in patients treated with entrectinib. ![]() NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.ġ Fabrizio, et al. ![]()
0 Comments
Leave a Reply. |